Despite recent progress in the treatment of CKD, such as the approval of sodium-glucose cotransporter-2 (SGLT2) inhibitors (Bakris et al., 2020; Heerspink et al., 2020), major therapeutic advances are still required to halt and reverse CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.